BEACON - A multi-user and multi-project facility for biological macromolecules and nanoparticles characterization in solution
Lead Research Organisation:
University of Sheffield
Department Name: Chemical & Biological Engineering
Abstract
Biological entities are composed of small molecules (e.g., water), macromolecules (proteins, nucleic acids, lipids, polysaccharides), supramolecular assemblies or macromolecular complexes, which assemble into subcellular organelles and cells, which in turn form supracellular systems such as tissues and organs. One of the key features of biological systems is the complex, specific or non-specific, intra- and inter-molecular interactions, which determine the structure and, further, the biological functions associated with the structure. As an example, hemoglobin is a tetrameric protein that binds and transports four oxygen molecules per unit and then releases them to myoglobin. The contacts between biological molecules, or biomolecular interactions, are also responsible for pathogen invasion and various diseases. SARS-CoV-2 virus binds to ACE2, the host target cell receptor, through the receptor binding domain of its spike protein. Neurodegenerative diseases such as Alzheimer's or Parkinson's are associated with the prion-like propagation and aggregation of toxic proteins. The ability to measure key physical parameters (e.g., mass, size, shape, interaction, and conjugation) of biological macromolecules and nanoparticles in solution will answer many FUNDAMENTAL QUESTIONS IN BIOLOGY and help us to understand THE RULES OF LIFE. Not only will the answers and the rules help to advance biotechnology and biological science, they guide our solutions to the grand challenges facing humanity (e.g., new and re-emerging diseases, epidemic, climate change, and sustainability etc). The aim of this proposal is to purchase a state-of-the-art equipment to enable biophysical measurements. The equipment will support a host of research projects underpinning BBSRC priorities, which neatly align with the visions of the four flagship institutes at the University of Sheffield (Healthy Lifespan, Neuroscience, Energy, and Sustainable Food). On top of that, the equipment allows the University COVID-19 response team to measure the quality of and quantify the biological reagents manufactured at the University to support diagnostic testing of coronavirus. The equipment also enhances our response and preparedness for current and future emergency. This equipment will be maintained by a dedicated team in the Department of Chemical & Biological Engineering at the University.
Technical Summary
The principal aim is to acquire an SEC|AF4|CG-MALS-DLS equipment for the University of Sheffield to conduct advanced biophysical characterization of macromolecules and nanoparticles in solution. The equipment combines the separation/mixing technology (SEC, AF4 and CG) and the light scattering technology (MALS and DLS). SEC and AF4 are 2-phase separation and 1-phase separation techniques, respectively. CG is a mixing technology using a multi-syringe pump system. It can be programmed to provide stop-flow injections at a series of well-defined concentrations or compositions. Through module arrangement, the equipment enables its users to perform three types of analyses: SEC-MALS-DLS, AF4-MALS-DLS and CG-MALS-DLS. This state-of-the-art equipment allows us to measure molar mass, size (RMS radius and hydrodynamic radius), conformation (shape, structure and branching parameters), interaction (binding affinity and stoichiometry), and conjugation (molecular weight and fraction of each constituent in a conjugate). The analysis can be performed on proteins, peptides, biopharmaceuticals, biopolymers, and nanoparticles (e.g., micelles, viruses, liposomes, polymersomes, and nanocapsules etc). Information derived from these measurements include native properties (oligomeric state), solution quality, size distribution, aggregation, protein stability, and protein unfolding, to name a few. This SEC|AF4|CG-MALS-DLS equipment will support a host of research projects underpinning BBSRC priorities. These projects include COVID-19 research, biopharmaceutical manufacturing, bioplastic production, RNA nuclear export, plant cell wall, amyloid formation, energy homeostasis, antibacterial drug, b-amino acids, crop protection, membrane remodelling, and high-cell-density cultivation of bacteria. These research activities align with the four flagship research institutes of the University of Sheffield (Healthy Lifespan, Neuroscience, Energy and Sustainable Food).
Description | (1) We have developed an analytical workflow to analyse virus particles using the FluMist samples provided by AstraZeneca. |
Exploitation Route | AstraZeneca is keen to continue the partnership with Sheffield, and to use biophysical method to optimise biomanufacturing of FluMist. |
Sectors | Healthcare Manufacturing including Industrial Biotechology Pharmaceuticals and Medical Biotechnology |
Description | We are very closed to spinning out a company called ReNewFood (we are finalizing the paperwork required for incorporation). |
Sector | Manufacturing, including Industrial Biotechology |
Impact Types | Societal Economic |
Description | ReNewFood |
Amount | £19,800 (GBP) |
Funding ID | NXW- EX-JAN23-02- SHEFFIELD |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 01/2023 |
End | 04/2023 |
Description | ReNewFood (IPDaC fund) |
Amount | £47,837 (GBP) |
Funding ID | X/015414 |
Organisation | University of Sheffield |
Sector | Academic/University |
Country | United Kingdom |
Start | 02/2023 |
End | 04/2024 |
Description | ReNewFood (IPDaC fund) |
Amount | £4,760 (GBP) |
Funding ID | X/015411 |
Organisation | University of Sheffield |
Sector | Academic/University |
Country | United Kingdom |
Start | 02/2023 |
End | 07/2023 |
Description | ReNewFood (IPDaC fund) |
Amount | £52,882 (GBP) |
Funding ID | X/185198 |
Organisation | University of Sheffield |
Sector | Academic/University |
Country | United Kingdom |
Start | 12/2023 |
End | 09/2024 |
Description | UK-South East Asia Vaccine Manufacturing Research Hub |
Amount | £7,600,000 (GBP) |
Funding ID | EP/Y009894/1 |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 11/2023 |
End | 03/2028 |
Description | Vaccine development in partnership with LMIC countries (ISPF ODA funding) |
Amount | £100,000 (GBP) |
Funding ID | RE-CL-2023-09 |
Organisation | United Kingdom Research and Innovation |
Department | Research England |
Sector | Public |
Country | United Kingdom |
Start | 01/2024 |
End | 03/2024 |
Description | 2nd collaborative project with AstraZeneca |
Organisation | AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | Myself and Dr. Adam Brown wrote the proposal on Synthetic Biology-Based Polymerase and Promoter Engineering for Production of Next-Generation mRNA Therapeutics |
Collaborator Contribution | (1) BBSRC iCASE studentship (2) £80000 cash contribution (3) Industrial placement for PhD student |
Impact | PhD student (Alessandra Sabatini) has started her PhD in Oct 2023. |
Start Year | 2023 |
Description | 3rd collaborative project with AstraZeneca |
Organisation | AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | I proposed to use BEACON suite to study influenza virus to improve the FluMist manufacturing process. |
Collaborator Contribution | Provision of influenza virus samples for analysis. |
Impact | We were able to produce excellent biophysical data using the samples from AstraZeneca. We are now discussing mechanisms to sustain this collaboration. |
Start Year | 2022 |
Description | 4th collaborative project with AstraZeneca |
Organisation | AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | We have established analytical workflow to analyze virus and virus-like particles. |
Collaborator Contribution | AstraZeneca is interested in virus-like particle (VLP) for vaccine development and manufacturing. |
Impact | AstraZeneca is now considering part-funding a PhD studentship. |
Start Year | 2024 |
Description | Partnership with AZ Cambridge |
Organisation | AstraZeneca |
Country | United Kingdom |
Sector | Private |
PI Contribution | Myself and Dr. Barbara Ciani (coI in this grant) formulated the research proposal to use BEACON suite to study coformulation of biologics. |
Collaborator Contribution | (1) AZ will provide cash contribution of £50000 to the project (2) AZ will host the PhD student involved for 3 months and cover the expenses incurred (£30000) (3) AZ will provide biologics for coformulation study (in-kind contribution of £600000) |
Impact | PhD student (Anyal Settle) is now working on the project. |
Start Year | 2022 |